September 17, 2010

Ei Yamada, CEO
AnGes MG, Inc.
(Code No.4563, TSE Mothers)
Contact: Fumihiko Suzuki, Manager, Business Planning Dept.
Tel: +81-3-5730-2480

FOR IMMEDIATE RELEASE

AnGes-MG to conduct an additional clinical trial for Collategene™, HGF Plasmid for Ischemic Disease Treatment

AnGes MG Inc. announced today that the company has decided to conduct an additional clinical trial for HGF Plasmid (INN: *beperminogene perplasmid*, Brand Name: Collategene™) for which it had submitted a New Drug Application (BLA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan.

AnGes-MG filed the BLA of Collategene™ on March 27, 2008, for Critical Limb Ischemia, and has conducted series of extensive consultations with the Pharmaceuticals and Medical Devices Agency (PMDA), a Japanese regulatory agency, which is responsible to conduct scientific reviews of NDAs, working together with the MHLW. As a result, while the effectiveness of Collategene™ has been confirmed in the Japanese phase 3 trial, it was concluded that further accumulation of evidence is required for the approval. Based on this conclusion, AnGes MG, Inc. made a decision to temporarily withdraw the application and to resubmit upon completion of the pending additional trial.

Currently, AnGes MG, Inc. is preparing for a global phase 3 clinical trial of Collategene™ under the US IND in the US, Europe, Japan and other countries. The protocol of this global trial has already received SPA (Special Protocol Assessment) approval by the FDA. In addition, as announced separately today, Collategene™ development program has obtained a Fast Track designation by the FDA. AnGes believes that by having Japanese sites participate in this global trial, Collategene™ will be approved in Japan in the most rapid and certain way. AnGes will continue its utmost effort to introduce a novel treatment option for Critical Limb Ischemia in Japan, as well as in the rest of the world.

By its decision to conduct an additional clinical trial, AnGes MG, Inc. has revised the business forecast that was announced on February 5, 2010.
For details, please refer to the announcement, “Revised Full-Year Business Forecasts.”

###